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Summary. Background: b2-Glycoprotein I (b2GPI) is an abun-
dant plasma protein that is closely linked to blood clotting, as it
interacts with various protein and cellular components of the
coagulation system. However, the role of b2GPI in thrombus
formation is unknown. We have recently shown that b2GPI is
susceptible to reduction by the thiol oxidoreductases thiore-
doxin-1 and protein disulﬁde isomerase, and that reduction of
b2GPI can take place on the platelet surface. Methods: b2GPI,
reduced by thioredoxin-1, was labeled with the selective
sulfhydryl probe N
a-(3-maleimidylpropionyl)biocytin and sub-
jected to mass spectrometry to identify the speciﬁc cysteines
involved in the thiol exchange reaction. Binding assays were
used to examine the aﬃnity of reduced b2GPI for von
Willebrand factor (VWF) and the eﬀect of reduced b2GPI on
glycoprotein (GP)Iba binding to VWF. Platelet adhesion to
ristocetin-activatedVWFwasstudiedinthepresenceofreduced
b2GPI. Results: We demonstrate that the Cys288–Cys326
disulﬁde in domain V of b2GPI is the predominant disulﬁde
reduced by thioredoxin-1. Reduced b2GPI in vitro displays
increased binding to VWF that is dependent on disulﬁde bond
formation. b2GPI reduced by thioredoxin-1, in comparison
with non-reduced b2GPI, leads to increased binding of GPIba
to VWF and increased platelet adhesion to activated VWF.
Conclusions: Given the importance of thiol oxidoreductases in
thrombus formation, we provide preliminary evidence that the
thiol-dependent interaction of b2GPI with VWF may contrib-
ute to the redox regulation of platelet adhesion.
Keywords:b2-glycoprotein I, oxidoreductase, platelet adhesion,
thioredoxin, von Willebrand factor.
Introduction
b2-Glycoprotein I (b2GPI) is a circulating plasma protein that
consists of ﬁve repeating amino acid domains [1,2]. b2GPI may
play a role in platelet adhesion as, in vitro, it interacts with von
Willebrand factor (VWF) [3] and the platelet receptors
glycoprotein (GP)Iba and ApoER2 [4,5]. b2GPI contains 11
disulﬁde bonds and no unpaired cysteine. The ﬁrst four
domains include four cysteines each, with disulﬁde bridges
joining the ﬁrst to the third and the second to the fourth
cysteine. The ﬁfth domain has an extra 20 amino acid tail, with
an unusual termination in a cysteine, that forms a loop-back
disulﬁde link with an extra cysteine found midway between the
standard second and third cysteine positions [1].
We have recently shown that b2GPI can be reduced by
thioredoxin-1 (TRX-1) and protein disulﬁde isomerase (PDI)
in vitro [6,7]. Thiol oxidoreductases are becoming increasingly
recognized as important mediators of platelet function [8,9].
The prototype member, PDI, is involved in regulation of
activation of the ﬁbrinogen receptoraIIbb3[10] and tissue factor
[11]. Several novel members of the thiol isomerase family have
been recently shown to translocate to the platelet surface
following platelet activation [12]. TRX-1 is another member of
the superfamily, and has been shown to protect endothelial
cells from oxidative stress [13,14]. Extracellular TRX-1 medi-
ates lymphocyte effector function [15] and may regulate platelet
adhesion [16]. We have shown that reduction of b2GPI is
achieved on the platelet surface and endothelial cells [6,7]. In
the current study, we show that b2G P Ii sr e d u c e db yT R X - 1a t
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  2010 International Society on Thrombosis and HaemostasisCys288–Cys326 in domain V of b2GPI, and that this reduction
results in a signiﬁcantly increased afﬁnity of b2GPI for VWF.
Materials and methods
Materials
Chemicals Reduced L-glutathione (GSH), apyrase, 1-chloro-
2,4-dinitrobenzene (DNCB), a-thrombin, HEPES, dithiothre-
itol (DTT), bovine serum albumin (BSA) and human serum
albumin(HSA)werefromSigma-Aldrich(StLouis,MO,USA).
N
a-(3-maleimidylpropionyl)biocytin (MPB) and NuPAGE 4–
12%Bis–TrisgelswerefromInvitrogenCorporation(Carlsbad,
CA, USA). Ristocetin was from Chrono-log (Havertown,
PA, USA). NADPH was from Calbiochem-Novabiochem
(San Diego, CA, USA). The bicinchoninic acid (BCA) Protein
Assay Reagent and p-nitrophenyl phosphate (pNPP)
substrate were from Pierce (Rockford, IL, USA). Streptavidin
96-well plates were from NUNC (Rochester, NY, USA).
Proteins Native b2GPI (nb2GPI) was from Haematologic
Technologies (Essex Junction, VT, USA) or was a generous gift
of I. Schousboe (University of Copenhagen, Denmark).
Recombinant b2GPI (rb2GPI), anti-b2GPI monoclonal
antibody (mAb) (clone 4B2E7) and afﬁnity-puriﬁed rabbit
polyclonal anti-b2GPI were generated in our laboratory as
previously described [17,18].
Recombinant human TRX-1 and recombinant GPIba were
fromR&D(Minneapolis,MN,USA)orAmericanDiagnostica
(Stamford, CT, USA). Recombinant rat thioredoxin reductase
(TRX-R) was from American Diagnostica. Recombinant hu-
manPDIwasfromMedical&BiologicalLaboratories(Woburn,
MA, USA).VWFwas from Calbiochem-Novabiochem.
Antibodies. Mouse anti-TRX-1 was from BD Bioscienc-
es (Cowley, UK). Mouse anti-human TRX-R was from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Streptavidin–
horseradish peroxidase (HRP), rabbit polyclonal anti-mouse
HRP and goat polyclonal anti-rabbit HRP antibodies were
from Dako (Glostrup, Denmark). Mouse anti-PDI (clo-
ne RL90) and mouse anti-VWF were from AbCam (Cam-
bridge, UK). Mouse anti-CD42b was from ABR-Afﬁnity
Bioreagents (Golden, CO, USA).
Methods
Structural analysis of b2GPI The structural features of all
disulﬁde bonds in two structures of b2GPI (Protein Data Bank
ID: 1C1Z and 1QUB) were determined with the disulﬁde bond
analysis tool available at http://www.cancerresearch.unsw.edu.
au/CRCWeb.nsf/page/Disulﬁde+Bond+Analysis.
The secondary structures, in which the cysteines reside, and
their solvent accessibility values are from DSSP (http://swift.
cmbi.ru.nl/gv/dssp/). The dihedral strain energy of the disul-
ﬁdes was estimated from the magnitude of the ﬁve vangles that
constitute the bond [19]. The analysis of the disulﬁde bonds in
b2G P Ii ss h o w ni nT a b l e1 .
Mass spectrometry To localize the speciﬁc cysteine(s) of
b2GPI that are reduced by TRX-1, nb2G P Iw a st r e a t e dw i t ha
TRX-1/TRX-R/NADPH mixture and labeled with the
selective sulfhydryl reagent MPB, on the basis of a previously
described method [20]. Speciﬁcally, TRX-1 (5 lM) was reduced
by incubation for 1 h at 37  C with TRX-R (10 nM)a n d
NADPH (200 lM) in a total volume of 300 lL. nb2GPI or
rb2GPI was added at a concentration of 0.2 lM to TRX-1/
TRX-R/NADPH and incubated for 1 h at 37  C. To label free
thiols, MPB at a concentration of 100 lM was added to b2GPI/
TRX-1/TRX-R/NADPH and incubated for 10 min at 37  C.
The reaction was quenched by the addition of GSH at a
concentration of 200 lM for 10 min at 37  C. All reactions
were performed in 20 mM HEPES buffer containing 0.14 M
NaCl (pH 7.4) (HBS).
Samples were separated by sodium dodecylsulfate polyacryl-
amide gel electrophoresis (SDS-PAGE) (4–12%) under non-
reducing conditions, and stained with Coomassie Blue stain.
The position of reduced (by TRX-1/TRX-R/NADPH)
b2GPI ± MPB on Bis–Tris gel after separation by SDS-
PAGE has been previously determined [6]. The corresponding
bands of b2GPI, reduced b2GPI and reduced b2GPI + MPB
were excised from the gel, and b2GPI peptides were prepared
and analyzed by mass spectrometry and MASCOT and X!TAN-
DEM searches (the preparation of b2G P Ip e p t i d e sa n da n a l y s i s
of biotinylation are provided in detail in Data S1).
Assays for binding of b2GPI to immobilized VWF
Binding of b2GPI reduced by TRX-1/TRX-R/NADPH to
immobilized VWF Ninety-six well microtiter plates were
coated with 100 lL of human VWF (10 lgm L
)1)i n0 . 1M
NaHCO3 (pH 8.3), as previously described [21]. Wells were
washed with HBS, and non-speciﬁc binding sites were blocked
by adding 200 lL of 2% BSA in HBS for 2 h at room
temperature; this was followed by washing with HBS. Eight
micromolar TRX-1 was incubated with 35 nM TRX-R and
180 lM NADPH for 1 h at 37  C. Reduced nb2GPI was
preparedbyincubating187 lLofnb2GPI(1.8 lM)orHBSwith
38 lL of TRX-1/TRX-R/NADPH for 1 h at 37  C. Reactions
were diluted 1 : 1 in HBS, and VWF-coated wells were
incubated with 100-lL reaction mixtures for 1 h at room
temperature. Wells were washed four times with HBS
containing 1 M NaCl, and 100 lLo fa n t i - b2GPI mAb
(20 lgm L
)1) was added and incubated for 1 h at room
temperature. After washing with HBS, 100 lL of a 1 : 1000
dilution of goat anti-mouse alkaline phosphatase (AP)-
conjugated antibody was added and incubated for 1 h at
roomtemperature.WellswerewashedwithHBS,and100 lLof
pNPP (1 mg mL
)1)i n1M diethanolamine buffer and 0.5 mM
MgCl2 ( p H9 . 8 )w a sa d d e dt oe a c hw e l l .I ns o m ee x p e r i m e n t s ,
free thiols in b2GPI/TRX-1/TRX-R/NADPH were blocked by
adding MPB (100 lM)fo r1 0m i na t3 7 C before addion of the
mixture to VWF-coated plates. In other experiments, TRX-R
wasinhibited,aspreviouslydescribed[22],byincubating3.5 lM
DNCB with TRX-R/NADPH before addition to TRX-1 (the
Reduced b2GPI and von Willebrand factor 1755
  2010 International Society on Thrombosis and Haemostasisﬁnal concentration of DNCB was 0.25 lM per well). The dose
response of binding of (reduced and non-reduced) nb2GPI to
immobilizedVWF(5 lgm L
)1)wasmeasuredbyaddingb2GPI
at concentrations between 0.01 and 4 lM.
To assess the effect of TRX-1/TRX-R/NADPH on the
capacity of immobilized VWF to bind to b2GPI, VWF-coated
wells were treated with or without 100 lL of TRX-1/TRX-R/
NADPH at concentrations equimolar to that used for
reduction of b2GPI. Subsequently, b2GPI was reduced with
TRX-1/TRX-R/NADPH, half of which was subsequently
incubated with DNCB (as described above), to inactivate
residual activity of TRX-R before it was added to VWF.
Binding of recombinant GPIba to immobilized VWF in the
presence of reduced nb2GPI vs. non-reduced b2GPI nb2GPI
or equimolar BSA was treated with TRX-1/TRX-R/NADPH
as above. Fifty-microliter volumes of the reaction mixtures
w e r ea d d e dt o5 0lL of recombinant GPIba (10 lgm L
)1)a n d
incubated for 1 h at 37  C. One-hundred-microliter volumes
of the reaction mixture were applied to VWF-coated wells.
The amount of GPIba bound was determined using 100 lL
of 1 lgm L
)1 anti-CD42b mAb and secondary anti-mouse
AP-conjugated antibody (1 : 1000).
Assays for binding of VWF to immobilized b2GPI
Binding of VWF in solution, in the presence or absence of
ristocetin, to immobilized reduced vs. non-reduced
b2GPI Non-reduced and reduced rb2GPI (reduced by
TRX-1/TRX-R/NADPH) were coated on ELISA plates at a
concentration of 10 lgm L
)1 for the b2GPI component,
according to Hulstein et al. [3]. One hundred microliters of
VWF (10 lgm L
)1) alone or after preincubation with
1m gm L
)1 ristocetin for 5 min at room temperature was
added to the wells and incubated for 1 h at room temperature.
For some experiments, 3.5 lM DNCB was incubated with
VWF or VWF/ristocetin before addition to immobilized
b2GPI.
To study the effect of TRX-1/TRX-R/NADPH on VWF in
solution, VWF (10 lgm L
)1) was incubated with or without
TRX-1/TRX-R/NADPH as above; half of the VWF mixture
was subsequently activated with ristocetin. These VWF mix-
t u r e sw e r et h e na d d e dt ow e l l sc o a t e dw i t hb2GPI. The amount
of bound VWF was assessed with the use of 100 lLo f
anti-VWF mAb (5 lgm L
)1) and secondary anti-mouse
AP-conjugated antibody (1 : 1000).
All enzyme-linked immunosorbent assay (ELISA) incuba-
tions were performed under argon, as exposure of reduced
b2GPI to air led to its gradual reoxidation [7].
The optical density (OD) for all binding assays was read at
405 nm with a Microplate Scanning Spectrophotometer (Bio-
Tek Instruments, Winooski, VT, USA).
Detection of TRX-1 and TRX-R in platelet lysates Washed
platelets from healthy donors were prepared as previously
described [20,23]. A platelet suspension, 4 · 10
11 L
)1 in 20 mM
HEPES, 137 mM NaCl, 4 mM KCl, 0.5 mM Na2HPO4 and
0.1 mM CaCl2 (pH 7.4) was activated with thrombin (100 nM)
Table 1 Properties of the b2-glycoprotein I (b2GPI) disulﬁde bonds in two X-ray structures of the protein [1,2]; analysis of the properties of the disulﬁde
bonds in b2GPI was performed as previously described [36,37]
PDB ID
Cys1
residue
Secondary
structure
Solvent
exposure
( A ˚ 2)
Cys2
residue
Secondary
structure
Solvent
exposure
( A ˚ 2)
Dihedral strain
energy
(kJ mol
)1) Classiﬁcation
1C1Z 4 b-Strand 0 47 Irregular 2 11.6 +/)RHSpiral
1C1Z 32 b-Strand 28 60 b-Strand 10 8.2 )LHSpiral
1C1Z 65 Irregular 6 105 b-Strand 2 14.7 )RHSpiral
1C1Z 91 b-Strand 28 118 b-Strand 11 7.9 )LHSpiral
1C1Z 123 b-Strand 0 169 b-Bridge 1 14.5 +/)RHSpiral
1C1Z 155 b-Strand 21 181 b-Strand 10 4.3 )LHSpiral
1C1Z 186 b-Strand 7 229 b-Bridge 0 15.7 )RHSpiral
1C1Z 215 b-Strand 32 241 b-Strand 7 7.4 )LHSpiral
1C1Z 245 b-Bridge 2 296 Irregular 0 9.3 +/)RHSpiral
1C1Z 281 Strand 2 306 Turn 33 18.7 +LHHook
1C1Z 288 Irregular 6 326 Irregular 117 11.1 )/+RHHook
1QUB 4 b-Strand 0 47 Irregular 1 9.2 +/)RHSpiral
1QUB 32 b-Strand 33 60 b-Strand 10 6.8 )LHSpiral
1QUB 65 Irregular 4 105 b-Strand 2 13.6 +/)RHSpiral
1QUB 91 b-Strand 32 118 b-Strand 18 6.3 )LHSpiral
1QUB 123 b-Strand 0 169 b-Bridge 1 10.1 +/)RHSpiral
1QUB 155 b-Strand 24 181 b-Strand 7 7.0 )LHSpiral
1QUB 186 b-Strand 10 229 b-Bridge 1 18.4 +/)RHSpiral
1QUB 215 b-Strand 33 241 b-Strand 8 4.8 )LHSpiral
1QUB 245 b-Bridge 4 296 Irregular 0 7.8 +/)RHSpiral
1QUB 281 b-Strand 1 306 Turn 31 12.2 +/)RHHook
1QUB 288 b-Strand 4 326 Irregular 103 12.2 )/+RHHook
PDB, Protein Data Bank; LH, left-handed; RH, right-handed.
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20 min at 4  C to isolate the platelet releasate, according to
Burgess et al.[20].Thepellet waswashed twicewithphosphate-
buffered saline, and lysed with lysis buffer NP40 containing
10% of a cocktail of proteinase inhibitors [4-(2-aminoethyl)
benzenesulfonyl ﬂuoride, pepstatin A, E-64, bestatin, leupeptin
and aprotinin]. The platelet lysate was obtained by
centrifugation at 2000 ·g for 20 min at 4  C. The protein
concentration was calculated with the microBCA assay. Equal
amounts of platelet lysate and releasate were subjected to 4–
12% Bis–Tris NuPage gel electrophoresis. Proteins were
transferred to poly(vinylidene diﬂuoride) membranes, and
TRX-1 and TRX-R were detected with mouse anti-human
TRX-1 (1 : 500) and mouse anti-human TRX-R (1 : 500)
antibodies. Anti-mouse HRP-conjugated (1 : 2000) antibody
was used as secondary antibody.
Platelet adhesion to reduced b2GPI coated on microtiter
wells in the presence of VWF The method is based on that
reportedbyLahavet al.[8].WashedplateletsinJamiesonbuffer
were pelleted and resuspended in platelet adhesion buffer (Tris-
buffered saline containing 0.05 M Tris-HCl, 140 mM NaCl,
2m M Mg
2+ and 0.1% BSA, pH 7.4) at 12 · 10
11 L
)1.N i n e t y -
six-wellplateswerecoatedwithnon-reducedorreducedrb2GPI
(reduced by TRX-1/TRX-R/NADPH), washed three times
withHBS,andincubatedwithVWFinthepresenceofristocetin
(1 mg mL
)1), as described above. Platelets in adhesion buffer
with or without TRX-1/TRX-R/NADPH or DNCB were
aliquoted into the corresponding (± TRX-1/TRX-R/
NADPH) wells and incubated at room temperature for 1 h.
After washing with phosphate-buffered saline (ﬁve times),
platelets that had adhered to the wells were visualized with a
Leica DM IRB(Leica,Wetzlar,Germany)microscope.Images
were obtained with a Leica DC200 (Leica) camera (· 10
magniﬁcation). The number of adherent platelets was
quantiﬁed by adding lysis buffer [0.07 M trisodium citrate,
0.3 M citric acid, 5 mM pNPP and 0.1% (v/v) Triton X-100,
pH 5.4]for1 h.Thereactionwasterminatedbyadditionof2 M
NaOH, and absorbance was read at 405 nm.
Statistical analysis
The SPSS 17.0 statistics software (SPSS Inc., Chicago, IL, USA)
was used for the analysis of data. Data were analyzed by
ANOVA followed by Dunnetts correction for multiple compar-
isons. A P-value of < 0.05 was considered to be statistically
signiﬁcant.
Results
Identiﬁcation of a free thiol in Cys326 of b2GPI after reaction
with TRX-1
Mass spectrometry showed biotinylation of nb2GPI treated
with TRX-1/TRX-R/NADPH/MPB (see Tables S1 and S2
for a full list of peptides for each sample). As a number
of cysteines were found to be biotinylated in b2GPI, the
MBP/iodoacetamide-labeled peptide ratio was used to deter-
mine the cysteine target of reduced TRX-1. As shown in
Table S3, Cys326 is by far the most heavily modiﬁed cysteine
in the protein.
Structural analysis of disulﬁde bond Cys288–Cys326 of the
b2GPI molecule
Nine of the 11 disulﬁdes in b2GPI have a spiral conﬁguration
(RHS, right-handed spiral or LHS, left-handed spiral), the
most common conﬁguration and one associated with structural
disulﬁdes (Table 1). The Cys288–Cys326 disulﬁde has a )/+
right-handed hook ()/+RHHook) conﬁguration in both
crystal structures of the protein [1,2]. None of the bonds are
particularly strained based on the measure of the dihedral
strain energy. Notably, Cys326 is particularly exposed to
solvent. This exposure is likely a factor in the reduction of the
Cys288-Cys326 disulﬁde bond by protein oxidoreductases.
Redox control of the interaction of b2GPI with VWF
Assays for binding of b2GPI to immobilized VWF. b2GPI
reduced by TRX-1 shows increased binding to immobilized
VWF. Given the importance of thiol linkage in VWF
multimerization [24] and its previously described ability to
bind b2GPI [3], we proceeded to examine whether free thiols
generated in b2GPI are involved in its interaction with VWF.
We applied b2GPI reduced by TRX-1/TRX-R/NADPH to
VWF-coated ELISA plates, and detected the amount of b2GPI
bound to VWF with the mAb 4B2E7. The binding of b2GPI
treated with TRX-1/TRX-R/NADPH to immobilized VWF
was increased 3.5-fold when compared with untreated b2GPI
(Fig. 1A). Non-reduced b2GPI displayed low binding to VWF,
regardless of the concentrations used, whereas binding of
reduced b2GPI to VWF showed a bell-shaped curve with
maximal binding at 0.8 lM (Fig. 1B) and decreased binding at
higher concentrations. This can be attributed to the high-dose
hook effectdescribed for high concentration of some ligands in
ELISA systems [25]. For a monotonic increase in signal with
concentration, there must be an excess of antibodies, both
capture and enzyme-conjugated, relative to the analyte being
detected. As the concentration of analyte (in this case, b2GPI)
begins to exceed the amount of antibody, the dose–response
curve will plateau and, with further increase, may,
paradoxically, become negatively sloped. In some cases, this
phenomenon has also been attributed to the coating density of
the capture antibody (the capture protein in this case being
VWF).
Thiol dependence of reduced b2GPI binding to VWF.
The increased binding of reduced b2GPI to immobilized VWF
was abrogated when the thiol-reactive molecule MPB was
added to reduced b2GPI (reduced by TRX-1/TRX-R/
NADPH) before addition to VWF-coated wells. This indicated
Reduced b2GPI and von Willebrand factor 1757
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disulﬁde bond formation between the two molecules, which
was prevented in the presence of MPB (Fig. 1A).
Inhibition of TRX-R activity by DNCB (before the
inclusion of TRX-R in the TRX-1/TRX-R/NADPH mixture
used to reduce b2GPI) decreased the binding of b2GPI treated
with TRX-1/TRX-R/NADPH to immobilized VWF, and the
binding was comparable to that of untreated b2GPI
(Fig. 1C).
Reduction of VWF by TRX-1 is not necessary for
interaction with b2GPI. There is evidence from the litera-
ture that exposure of VWF to TRX-1/DTT reduces disulﬁde
bonds in the molecule, decreasing the binding afﬁnity of
collagen [21]. To exclude the effect of TRX-1/TRX-R/
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Fig. 1. Assays for binding of reduced vs. non-reduced b2-glycoprotein I (b2GPI) to immobilized von Willebrand factor (VWF). Thiol dependence of the
b2GPI–VWF interaction. Reduced b2GPI promotes binding of glycoprotein (GP)Ibato VWF. (A) Increased binding of reduced native b2GPI (nb2GPI) to
VWF; inhibition by the thiol blocker N
a-(3-maleimidylpropionyl)biocytin (MPB). Plates were coated with VWF, and b2GPI mixtures were applied to the
wells and incubated for 1 h at room temperature. The amount of bound b2GPI was assessed with an anti-b2GPI monoclonal antibody (mAb). b2GPI
reduced by thioredoxin-1 (TRX-1)/thioredoxin reductase (TRX-R)/NADPH showed a signiﬁcantly higher level of binding to VWF than non-reduced
b2GPI. The increased binding of reduced b2GPI to VWF was inhibited when free thiols introduced into b2GPI by TRX-1/TRX-R/NADPH were
previously blocked with MPB. (B) Dose–response curves of nb2GPI (reduced and non-reduced) binding to immobilized VWF. The amount of bound
b2GPI was assessed with an anti-b2GPI mAb. Maximal binding for b2GPI reduced by TRX-1/TRX-R/NADPH is at 0.8 lM (n = 2). (C) Inhibition of
reduced nb2GPI binding to VWF by the TRX-R inhibitor 1-chloro-2,4-dinitrobenzene (DNCB). Plates were coated with VWF and blocked. TRX-R
activity was inhibited by DNCB before incubation with TRX-1. b2GPI was treated with the inactive TRX-1 preparations and applied to the wells. The
amount of b2GPI bound to VWF was signiﬁcantly reduced when TRX-R had been inactivated with DNCB. (D) The increased binding of reduced nb2GPI
to VWF is mediated through the eﬀect of the TRX-1 reducing mixture on b2G P Ia n dn o to nV W F .P l a t e sw e r ec o a t e dw i t hV W Fa n db l o c k e d .V W F -
coated wells were then treated with TRX-1/TRX-R/NADPH or buﬀer alone. Separately, nb2GPI was incubated with TRX-1/TRX-R/NADPH, and half
of the mixture was incubated with DNCB to inactivate residual TRX-R activity before addition of the b2GPI preparations to the wells. Binding of b2GPI
w a sd e t e r m i n e dw i t ha na n t i - b2GPI mAb. The binding of reduced b2GPI to VWF was not aﬀected by pretreatment of the coated VWF with TRX-1/TRX-
R/NADPH before addition of the b2GPI mixtures. Also, inhibition of the residual TRX-R activity contained in the b2GPI/TRX-1/TRX-R/NADPH
mixture before addition to coated VWF did not alter the binding of already reducedb2GPI to VWF (whether or not VWF was exposed to active TRX-R or
DNCB-inactivated TRX-R). (E) Binding of recombinant GPIba to immobilized VWF in the presence of reduced nb2GPI. Plates were coated with VWF
andblocked. b2GPI withor without TRX-1/TRX-R/NADPH treatment and bovine serum albumin treatedwith TRX-1/TRX-R/NADPH as control were
incubated with GPIba. The reaction mixtures were then applied to the wells and incubated. The amount of GPIba bound was determined with a speciﬁc
anti-GPIba mAb, and was increased in the presence of reduced b2GPI. OD, optical density; b2, b2GPI; M, MPB; TRN, TRX-1/TRX-R/NADPH; B,
bovine serum albumin; NS, not signiﬁcant. For all enzyme-linked immunosorbent assays, values are the mean ± standard error of the mean (n =3 ) .
***P < 0.001.
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approaches. First, we treated VWF coated on the wells with
TRX-1/TRX-R/NADPH or buffer alone, and compared
binding afﬁnities for b2GPI. Treatment of VWF with the
reducing mixture before addition of b2GPI did not affect
b2GPI binding: non-reduced b2GPI showed low binding to
VWF, whether or not VWF had been pretreated with TRX-1/
TRX-R/NADPH. Also, reduced b2GPI showed a high level of
binding to VWF, whether or not VWF had been pretreated
with TRX-1/TRX-R/NADPH (Fig. 1D).
In the second approach, we utilized the TRX-R inhibitor
DNCB to inactivate the residual reducing activity of TRX-1/
TRX-R/NADPH after it had already reduced b2GPI. When
DNCB had been incubated with TRX-1/TRX-R/NADPH
before it was used to reduce b2GPI, b2GPI could not be
reduced,andthereforethemixtureofb2GPIandinactiveTRX-
1/TRX-R/NADPH showed the same low level of binding to
VWF as b2GPI alone (Fig. 1C). However, when DNCB was
addedtoTRX-1/TRX-R/NADPH after it had already reduced
b2GPI, b2GPI/inactivated TRX-1/TRX-R/NADPH showed
the same high level of binding as b2GPI/active TRX-1/TRX-R/
NADPH, thus showing that the critical event in VWF–b2GPI
binding is the reduction of b2GPI (Fig. 1D).
b2GPI reduced by TRX-1 promotes binding of GPIba to
immobilized VWF. Thepresenceofreduced b2GPI(reduced
by TRX-1/TRX-R/NADPH) increased the binding of GPIba
to immobilized VWF in comparison with untreated b2GPI or
BSA treated with TRX-1/TRX-R/NADPH as control protein
(Fig. 1E).
Assays for binding of VWF to immobilized b2GPI. Depen-
dence of VWF binding to reduced b2GPI on ristocetin
activation of VWF. Ristocetin-activated VWF bound more
than non-activated VWF to coated, non-reduced b2GPI.
Furthermore, there was a signiﬁcant increase in the binding
of ristocetin-activated VWF to coated, reduced b2GPI as
compared with non-activated VWF (Fig. 2A). This shows that
the afﬁnity of reduced b2G P If o rV W Fi sh i g hw h e nV W Fi s
activated either by coating on microtiter wells (Fig. 1A) or
being treated in solution with ristocetin (Fig. 2A). Incubating
TRX-1/TRX-R/NADPH with VWF in solution did not affect
its capacity to bind to b2GPI (Fig. 2A).
The binding of VWF (activated or non-activated by
ristocetin) to immobilized (reduced or non-reduced) b2GPI
was not affected by the presence or not of DNCB in the VWF
solution (Fig. 2B).
Potential role of reduced b2GPI and TRX-1 in platelet
adhesion
TRX-1 and TRX-R are detected by western blot in platelet
lysates As VWF tethers platelets, we were interested to
determine whether the source of b2GPIs reducing agent, TRX-
1, can be found in platelets. Both TRX-1 and TRX-R were
detected in platelet lysates of resting and thrombin-activated
platelets.TRX-1 wasalsodetected inthereleasatesfrom resting
and thrombin-activated platelets (Fig. 3A).
b2GPI reduced by TRX-1 increases platelet adhesion to
activated VWF The VWF–platelet GPIba receptor
interaction is important for the initial step of platelet
adhesion. Ristocetin promotes VWF binding to GPIba in
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Fig. 2. Assays for binding of von Willebrand factor (VWF) in solution to
immobilized b2-glycoprotein I (b2GPI). Ristocetin-activated VWF has
increased aﬃnity for reduced b2GPI. Dependence of VWF–b2GPI binding
on the reduction state of b2GPI. (A) Ristocetin activation of VWF in-
creases binding to immobilized reduced recombinant b2GPI (rb2GPI).
Non-reduced and reduced rb2GPI [reduced by thioredoxin-1 (TRX-1)/
thioredoxin reductase (TRX-R)/NADPH] were coated on enzyme-linked
immunosorbent assay (ELISA) plates (under argon) at a concentration of
10 lgm L
)1fortheb2GPI component.Afterwashing, VWF(10 lgm L
)1)
was added alone or after incubation with TRX-1/TRX-R/NADPH (at the
same concentration and with the same method as used for the reduction of
b2GPI). Half of the VWF solution was further incubated with ristocetin
before addition to the wells. The amount of bound VWF was assessed with
an anti-VWF monoclonal antibody. Ristocetin-activated VWF showed a
marked increase in binding to reduced b2G P Ia sc o m p a r e dw i t hn o n -
activated VWF.Treatment of VWF in solution with the reducing mixture
TRX-1/TRX-R/NADPH did not aﬀect its binding to b2GPI in the pres-
ence or absence of ristocetin. (B) Binding of VWF to coated b2GPI in the
presence of 1-chloro-2,4-dinitrobenzene (DNCB). Reduced and non-re-
duced b2GPI (reduced by TRX-1/TRX-R/NADPH) was coated onto 96-
well plates under argon. Preparations of VWF or VWF activated by
ristocetin were prepared, and half of these were incubated with DNCB.
The VWF mixtures were added to the wells and incubated for 1 h at room
temperature. Detection with an anti-VWF antibody showed that the
presence of DNCB did not aﬀect the binding of VWF to already reduced
b2GPI on the plate. OD, optical density; b2, b2GPI; TRN, TRX-1/TRX-
R/NADPH; risto, ristocetin; NS, not signiﬁcant. For all ELISAs, values
are the mean ± standard error of the mean (n = 3). ***P < 0.001.
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a greater afﬁnity for reduced b2GPI (Fig. 2A), so we tested
whether reduced b2GPI could support platelet adhesion. The
method was based on one previously published, which uses an
ELISA to measure acid phosphatase in adherent platelets [8].
In this system, reduced b2GPI caused a signiﬁcant increase, by
41%, in platelet adhesion as compared with non-reduced
b2GPI when VWF was activated with ristocetin (OD 0.68 ±
0.04 vs. 0.40 ± 0.02, respectively, mean ± standard
deviation, n = 3 in triplicate, P < 0.0001). Platelet adhesion
was partially inhibited by addition of the TRX-R inhibitor
DNCB, supporting the notion that reduction of b2GPI by
TRX-1 was partially responsible for the adhesion of the
platelets (Fig. 3B). Representative images of the platelet
adhesion assay are shown in Fig. 3C. Platelets displayed low
adhesion to VWF not treated with ristocetin, with no
differences being seen between coated b2GPI, HSA, TRX-1-
treated b2GPI or TRX-1-treated HSA (data not shown).
Discussion
In the current study, we have shown that b2GPI reduced by
TRX-1 demonstrates thiol-dependent increased binding to
VWF and platelet adhesion to activated VWF. TRX-1 is
ubiquitously expressed and is secreted to the cell surface [26].
TRX-1 is also present in platelet lysates [27] and releasates. We
have previously shown that b2GPI is partially reduced on the
platelet surface by TRX-1/TRX-R/NADPH [6]. We now
demonstrate that the predominant cysteine reduced by TRX-1
is Cys326 in domain V. This ﬁnding is in agreement with the
majority of biological functions of b2GPI being attributed to
domain V including phospholipid [1], thrombin [28] and
GPIba binding [4,5], and FXIa cleavage [29]. The ﬁfth domain
is predicted to be anchored to the plasma membrane, providing
the appropriate interface to react with cell surface proteins such
as platelet oxidoreductases.
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Fig. 3. Detection of thioredoxin-1 (TRX-1) and thioredoxin reductase
(TRX-R) in platelets. b2-glycoprotein I (b2GPI) reduced by TRX-1 in-
creases platelet adhesion to activated von Willebrand factor (VWF). (A)
Platelets as a source of TRX-1 and TRX-R. Western blotting of TRX-1
under reducing conditions in lysates of resting (lane 2) and thrombin-
activated (lane 3) platelets, and releasates of resting (lane 4) and thrombin-
activated (lane 5) platelets. Detection of TRX-R was conﬁrmed on non-
reduced proteins of platelet lysate of thrombin-activated platelets (lane 2)
and resting platelets (lane 3). Lane 1 shows the band for recombinant
human TRX-1 (400 ng) and recombinant rat TRX-R (250 ng), respec-
tively. Platelet lysates (1.5 lg) were loaded in lanes 2 and 3, and platelet
releasate (5 lg) in lanes 4 and 5. (B) Platelet adhesion to reduced b2GPI is
enhanced in the presence of activated VWF. Recombinant b2GPI
(rb2GPI) was treated or not treated with TRX-1/TRX-R/NADPH and
coatedonto96-wellplates. After blocking, wellswere incubatedwithVWF
activated with ristocetin. Platelets in adhesion buﬀer with or without
TRX-1/TRX-R/NADPH or 1-chloro-2,4-dinitrobenzene (DNCB) were
aliquoted into the corresponding (± TRX-1/TRX-R/NADPH) wells and
incubated at room temperature for 1 h. After extensive washing with
phosphate-buﬀered saline, platelets that had adhered were quantiﬁed with
lysis buﬀer for 1 h. The reaction was terminated by the addition of 2 M
NaOH, and absorbance was read at 405 nm. OD, optical density; b2,
b2GPI; TRN, TRX-1/TRX-R/NADPH; HSA, human serum albumin.
Values are the mean ± standard error of the mean (n = 3, in triplicate).
***P < 0.001. (C) Representative images of platelet adhesion obtained
w i t haL e i c aD C 2 0 0c a m e r aa t· 10 magniﬁcation. b2GPI reduced by
TRX-1/TRX-R/NADPH signiﬁcantly enhanced plateleta d h e s i o nt ov W F
activated by ristocetin, whereas non-reduced b2GPI or TRX-1/TRX-R/
NADPH-treated HSA did not. Platelet adhesion was partially inhibited
when TRX-1/TRX-R/NADPH was treated with DNCB.
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GPIba and VWF [3–5]. Hulstein et al. [3] showed that b2GPI
bound to the A1 domain of VWF with low afﬁnity and
inhibited platelet adhesion to immobilized VWF. However,
when free thiols are introduced into b2GPI by TRX-1, the
binding afﬁnity for VWF increases signiﬁcantly and promotes
adhesion of GPIba and platelets to activated VWF. The
GPIba–VWF interaction is crucial for hemostasis. Disulﬁde
exchange may be an important feature of platelet tethering to
exposed VWF, as shear has been shown to promote disulﬁde
formation between VWF subunits and VWF binding to
platelets [24]. Furthermore, GPIba shows physical proximity
to PDI on the platelet surface [20]. Platelets may also provide
the surface for reduction of b2GPI, which could be a modiﬁer
of disulﬁde reactions of VWF and/or GPIba.
Multiple interactions of b2GPI have been shown with
various components of the coagulation and ﬁbrinolysis system
in vitro, often with conﬂicting results and interpretations.
Although b2GPI deﬁciency does not lead to gross hemostatic
abnormalities, we believe that reduction of circulating b2GPI
can promote thrombus formation under speciﬁc conditions.
This idea is supported by the facts that b2GPI
)/) mice have
impaired thrombin generation [30] and that b2GPI inhibits
thrombin inactivation by heparin cofactor II [31]. Our labora-
tory has shown that b2GPI is predominantly in the reduced
form in vivo [7]. Hence, it is possible that in vivo reduced b2GPI
supports platelet adhesion, a function not apparent in in vitro
studies, where the puriﬁed protein has been signiﬁcantly
oxidized. The design of in vivo studies would delineate the role
of reduced vs. non-reduced b2GPI in platelet adhesion.
The presence of the reduced form of b2GPI in the circulation
may be relevant to disease development. There are a number of
publications addressing the relationship of b2GPI levels to
thrombotic and atherothrombotic disease, some in the context
of antiphospholipid syndrome. In a review by Inanc et al. [32],
the levels of circulating b2GPI was not associated with
thrombotic risk. High levels of circulating b2GPI have been
reported to decrease the risk of myocardial infarction in elderly
men [33]. With regard to the risk of thrombosis, the amount of
reduced b2GPI in the circulation may be more important than
the total levels of circulating b2GPI.
The ﬁnding for the ﬁrst time that b2GPI can be involved in
thiol exchange reactions with TRX-1 is of considerable impor-
tance, given b2GPIs high concentration in plasma makes it
easily available for reactions where thiols are needed. There is
increased scientiﬁc interest in the role of thiol-acting enzymes
suchasPDIinthrombusformation.PDIhasbeenshownin vivo
to be required for thrombus formation [34] and tissue factor
activation [35]. Inhibition of PDI action by an inhibitory
antibody or the thiol blocker bacitracin abrogated thrombus
formation.AlthoughthesubstrateofPDIhasnotbeendeﬁnitely
established, existing data support integrin aIIbb3or GPIba. The
demonstration that b2G P Ii sas u b s t r at eo fT R X -1a n dP D Ih a s
implications for a role of b2GPI in thrombus formation. Our
resultsalsoprovideconsiderableinsightintotheparticipationof
extracellular TRX-1 in the regulation of platelet adhesion.
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